Previous Article | Next Article 
J Virol, March 1998, p. 2047-2054, Vol. 72, No. 3
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Construction and Characterization of a
Temperature-Sensitive Human Immunodeficiency Virus Type 1 Reverse
Transcriptase Mutant
Mingjun
Huang,
Ralf
Zensen,
Michael
Cho, and
Malcolm A.
Martin*
Laboratory of Molecular Microbiology,
National Institute of Allergy and Infectious Diseases, Bethesda,
Maryland 20892
Received 21 August 1997/Accepted 20 November 1997
 |
ABSTRACT |
A temperature-sensitive (ts) human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase (RT) mutant was generated by charged-cluster-to-alanine mutagenesis. The mutant virus, containing three charged residues within the RT finger domain changed to alanine
(K64A, K66A, and D67A), replicated normally at 34.5 but not 39.5°C.
Quantitating virus particle production by p24 antigen capture or
virion-associated RT activity and virus infectivity by the MAGI cell
assay, we found that (i) mutant virions produced at the permissive
temperature were indistinguishable from wild-type virus in assays
performed at the nonpermissive temperature, suggesting that the
ts mutation did not impair early steps in the virus
replication cycle and that the mutant RT enzyme was not ts;
and (ii) virus particle production in cells transfected with the
ts mutant at the nonpermissive temperature was comparable
to that of wild-type virus. However, the particle-associated RT
activity and infectivity of mutant virions produced at the
nonpermissive temperature were greatly reduced when assays were
conducted at the permissive temperature. These results are consistent
with an irreversible ts event affecting RT that occurs
during virus particle production. Radioimmunoprecipitation analyses
revealed that both p66 and p51 RT subunits were absent from mutant
virions generated at 39.5°C. The presence of normal levels of HIV-1
integrase in mutant particles produced at the nonpermissive temperature
was inconsistent with defective Gag-Pol synthesis or Gag-Pol
incorporation into progeny virions. Furthermore, wild-type levels of
the mutant Pr160gag-pol were detected in
virions produced at the nonpermissive temperature when the HIV-1
protease was inactivated by site-specific mutagenesis. Taken together,
these results are most consistent with a ts defect affecting the degradation or aberrant processing of the mutated RT
during its processing/maturation within nascent particles.
 |
INTRODUCTION |
The conversion of viral genomic RNA
into unintegrated double-stranded linear DNA molecules during the early
phase of the productive virus infection is the signature of
Retroviridae. This reaction is catalyzed by reverse
transcriptase (RT), encoded by the highly conserved pol gene
found in retroviruses and eukaryotic retrotransposable elements. In the
case of human immunodeficiency virus type 1 (HIV-1), the mature RT is a
heterodimer (13), consisting of 66- and 51-kDa subunits that
are colinear at their N termini. The larger subunit contains DNA
polymerase and RNase H domains, whereas p51 lacks the C-terminal RNase
H domain. Retroviral RTs possess two enzymatic activities: (i) a DNA
polymerase that can use RNA or DNA templates and (ii) RNase H, which
degrades genomic RNA present in DNA-RNA intermediates.
Crystal structures of unligated HIV-1 RT (44) or RT
complexed with the non-nucleoside inhibitor Nevirapine (28)
or an 18/19-mer oligonucleotide (23) have been reported. The
structure of the polymerase domain of the 66-kDa component within the
heterodimer has been likened to a right hand, possessing finger, palm,
thumb, and connection domains. Although the same subdomains are present in p51, they differ in arrangement: both the DNA binding groove and
polymerase active site of p66 are missing from p51.
As is the case for other retroviruses, the pol gene of HIV-1
encodes a high-molecular-weight Gag-Pol precursor
(Pr160gag-pol) that is incorporated
into nascent particles as a result of its noncovalent association with
the Gag precursor polyprotein Pr55gag (40,
47, 54). Processing of Pr160gag-pol by the
HIV-1-encoded protease (PR) during virus budding from the cell membrane
gives rise to the mature, virion-associated PR and integrase (IN)
proteins as well as the p66 and p51 forms of the RT heterodimer
(25). Subsequent to adsorption, fusion, and entry into a
newly infected cell, the particles are partially uncoated and commence
synthesizing DNA copies of their genomic RNAs as they
traverse the cytosol. Thus, the generation of full-length linear viral
DNAs by RT during the early phase of infection reflects the successful
completion of multiple biosynthetic, metabolic, and enzymatic reactions
in both the virus-producing and newly infected cells.
The identification and characterization of RT mutants has proven to be
invaluable for integrating structural and functional properties of this
critical HIV-1 protein. Both in vitro mutagenesis of the HIV-1 RT and
studies of drug-resistant RT variants have delineated several
functionally important domains, the majority of which involve its
DNA-polymerizing activity (2-9, 11, 16, 22, 24, 26, 30, 32-34,
36, 43). We have attempted to create conditional RT mutants
affected in one or more of the myriad of processes and functions that
must be completed during a productive virus infection. The
charged-cluster-to-alanine mutagenesis approach, previously used to
generate temperature-sensitive (ts) mutants of cellular and
viral genes (12, 19, 50, 55), was employed to alter exposed
regions of the HIV-1 RT. Such mutants may exhibit impaired interaction
with other cellular or viral proteins or be unable to stably associate
with the viral RNA template or the DNA product of the reverse
transcription reaction.
In this report, we describe the construction and characterization of a
ts mutation affecting the HIV-1 RT. When charged residues at
positions 64, 66, and 67 within the finger domain of RT were changed to
alanine, the resultant virus replicated at the permissive (34.5°C)
but not the restrictive (39.5°C) temperature. Further characterization of the ts mutant indicated that progeny
virions produced at 39.5°C possessed no RT activity, contained no
detectable or only background levels of p66 and p51, and were not
infectious. In contrast, the mutant (mt4) particles produced at
34.5°C possessed RT activity when assayed at 34.5 or 39.5°C,
contained the RT heterodimeric protein, and were infectious in MAGI
cells at both temperatures. The ts step in the life cycle of
mt4 occurs in virus-producing cells subsequent to the incorporation of
Pr160gag-pol, very likely during the processing
of the Gag-Pol precursor in nascent particles.
 |
MATERIALS AND METHODS |
Construction of RT mutants.
Recombinant plasmids were
constructed and used to transform bacteria by standard procedures. The
full-length infectious molecular clone of HIV-1LAI (pLAI
[41]) was used in these experiments as the wild-type
control and as the source of mutant derivatives. A 2,219-bp
BclI-EcoRI fragment (nucleotides 2511 to 4730)
from pLAI was subcloned into M13mp18. Oligonucleotide-directed
mutagenesis was performed as previously described (29) to
construct 33 charged-cluster-to-alanine mutations within the RT coding
region of the pol gene. We defined a charged cluster as
containing at least two charged amino acid residues within a group of
five consecutive residues. In most mutants, at least two charged
residues within a cluster were changed, although occasionally only one
residue was altered. Each set of mutations created a novel
BstUI restriction endonuclease site which allowed the
presence of the introduced mutations to be readily identified. A
1,057-bp BclI-PflMI (nucleotides 2511 to 3568) or a 1,162-bp PflMI-EcoRI (nucleotides 3568 to 4730)
fragment, carrying the desired mutation, was excised from the
mutagenized DNA and cloned back into pLAI. The presence of putative
mutations in viral mutants that failed to replicate following
transfection of CEM (12D7) cells and the absence of undesired
changes in subcloned pol gene segments were confirmed by DNA
sequencing.
Cell culture, transfection, and infection.
HeLa cells were
maintained in Dulbecco's modified essential medium (DMEM) supplemented
with 5% fetal bovine serum, 100 U of penicillin G sodium per ml, and
0.1 mg of streptomycin sulfate per ml at 37°C unless otherwise
specified. HeLa cells were transfected by the calcium phosphate
precipitation method as previously described (14).
Forty-eight hours posttransfection, culture supernatants were tested
for RT activity and p24 Gag protein as outlined below. Transfected cell
supernatants were filtered through a 0.45-µm-pore-size filter for use
as virus stocks.
CEM (12D7) cells (45) were propagated in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 100 U of penicillin G sodium
per ml, and 0.1 mg of streptomycin sulfate per ml. CEM (12D7) cells
were transfected using DEAE-dextran or infected with cell-free virus
preparations as previously described (14). For infections,
an amount of the wild-type HIV-1LAI, prepared at 37°C from transfected HeLa cells, equivalent to 106
32P-RT cpm was used to infect 5 × 106 CEM
(12D7) cells. This HIV-1LAI inoculum contained
approximately 5 ng of p24 Gag protein; this amount of ts
mutant virus was also used in infectivity assays.
The CD4-positive long terminal repeat-

-galactosidase-expressing
HeLa (MAGI) cell indicator line (
27) was obtained from
the
AIDS Research and Reference Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, and maintained in
DMEM
supplemented with 5% fetal bovine serum, 100 U of penicillin
G sodium
per ml, 0.1 mg of streptomycin sulfate per ml, 0.2 mg
of G418 sulfate
per ml, and 0.1 mg of hygromycin B per ml. Cells
were seeded at a
density of 4 × 10
4 per well in a 24-well plate
24 h prior to infection. Samples
of virus (5 ng of p24 in 150 µl) were adsorbed to cells in the
presence of 3 µg of DEAE-dextran
for 3 h at 34.5°C, 2 h at 37°C,
or 1 h at 39.5°C
prior to the addition of 1 ml of medium. Following
incubation for
72 h at 34.5°C, 48 h at 37°C, or 40 h at 39.5°C,
the cells were fixed and stained with
5-bromo-4-chloro-3-indolyl-

-
D-galactopyranoside
(X-Gal)
as previously described (
27).
RT and p24 assays.
The RT assay was performed as reported
previously (51), with the addition of 0.8 mM EDTA to the
reaction cocktail. Briefly, 10 µl of cell-free supernatant from
infected-transfected cells was added to 50 µl of RT cocktail for
3 h at 37°C unless otherwise specified. A 5-µl aliquot was
spotted onto DE-81 paper, washed three times with 2× SSC (1× SSC is
0.15 M NaCl plus 0.015 M sodium citrate), and counted in a liquid
scintillation counter.
The amount of p24 Gag protein in cell-free supernatants was determined
by enzyme-linked immunosorbent assay (Coulter Immunology),
using the
instructions and standards supplied by the manufacturer.
Samples from
transfected CEM (12D7) cultures were diluted 2,000-
to 4,000-fold in
RPMI 1640 medium containing 10% fetal bovine
serum, and samples from
transfected HeLa cultures were diluted
5,000- to 10,000-fold in DMEM
containing 5% fetal bovine serum
so that they were in the linear range
of the assay.
Metabolic labeling and radioimmunoprecipitation.
The
procedure used for metabolic labeling of transfected HeLa cells has
been previously described (21), although the incubation temperatures were modified for these experiments. Cells were initially transfected at 37°C for 3 h. The cultures were then incubated at
34.5°C for 54 h or at 39.5°C for 40 h and then labeled
for 16 h at 34.5°C or 12 h at 39.5°C.
Transfected CEM (12D7) cells were incubated at 36 ± 0.5°C, and
the medium was changed at 2-day intervals up to the time when
syncytium
formation was first observed (usually around 11 days
posttransfection).
Cells from 6-ml cultures (approximately 10
7 cells) were
pelleted, washed, and plated in 25-cm
2 tissue culture
flasks in 2 ml of methionine-free RPMI 1640 medium
supplemented with
10% fetal bovine serum. [
35S]methionine (500 µCi) was
added, and the cells were incubated
for 16 h at 34.5°C or for
12 h at 39.5°C. Following the labeling
period, the cells were
harvested and pelleted by a brief spin
in a microcentrifuge. The
cell-free supernatants were filtered
through a 0.45-µm-pore-size
filter, and virion-associated proteins
were collected by pelleting for
30 min at 35,000 rpm in an SW50.1
rotor (Beckman).
Pulse-chase experiments were initiated when syncytia became visible in
transfected CEM (12D7) cells maintained at 36 ± 0.5°C
(approximately on day 10 or 11). Cells from 6 ml of CEM (12D7)
cultures
were used for each pulse-chase experiment. The remaining
steps were
performed as described previously (
53) except that
the
incubation temperature was maintained at either 34.5 or 39.5°C.
At
the conclusion of each pulse and chase period, the CEM (12D7)
cells
were pelleted and the supernatants were filtered. To obtain
virion-associated proteins, 200 µl of cell-free supernatant was
pelleted for 99 min at 14,000 rpm in a Tomy high-speed microcentrifuge.
The cell-free, virion-free supernatant fractions from the
microcentrifugation
were also collected after each spin.
Immunoprecipitation was carried out as previously described
(
52) with the indicated antibodies. AIDS patient sera and a
sample of a rabbit anti-HIV-1 RT polyclonal antibody (anti-RT
Ab 1)
were obtained from National Institute of Allergy and Infectious
Diseases AIDS Research and Reference Reagent Program (human HIV
immune
globulin, catalog no. 192; rabbit HIV-1 RT antiserum, catalog
no. 634).
Another anti-HIV-1 RT rabbit polyclonal antibody (anti-RT
Ab 2) was
purchased from Intracell (Cambridge, Mass.), and anti-HIV-1
IN
monoclonal antibody 35 was generously provided by Stephen Hughes.
All
precipitates were subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) analysis in 10% acrylamide-AcrylAide
(FMC) gels. The gels were fixed in methanol and acetic acid, treated
with 1 M salicylic acid, dried at 100°C, and placed on Biomax
MR film
(Kodak).
Immunoblot analysis of virion-associated proteins.
Cell-free
supernatants from transfected HeLa cells were pelleted as described
above. Equivalent amounts of each virus preparation, as measured by p24
content, were subjected to SDS-PAGE (10% gel) and then transferred to
nitrocellulose membranes. Binding of an anti-HIV-1 RT rabbit polyclonal
antibody (Intracell) to virion-associated RT subunits was visualized by
chemiluminescence using horseradish peroxidase-conjugated goat
anti-rabbit immunoglobulin G as described in the protocol of the
manufacturer (Pierce).
 |
RESULTS |
Construction and properties of an RT ts HIV-1
mutant.
The charged-cluster-to-alanine mutagenesis approach
(12, 19, 50, 55) was used to generate potential
ts mutations affecting HIV-1 RT coding sequences. This
mutagenesis protocol, outlined in Materials and Methods, involved the
substitution of alanine residues in charged regions of the RT coding
segment of the pLAI infectious molecular clone, which was derived from
the HIV-1LAI isolate (41). pLAI DNAs, containing
different mutagenized RT regions, were transfected into HeLa and CEM
(12D7) cells, and progeny virus production at 34.5, 37, and 39.5°C
was monitored by RT activity released into the medium. None of these RT
mutations conferred a ts phenotype, although several
resulted in mutant viruses that had lost infectivity for CEM (12D7)
cells at all temperatures tested (Table
1). One of these (mt1), with alterations affecting amino acids 64 through 67 of RT, failed to establish a
spreading infection in CEM (12D7) cells but did generate wild-type levels of progeny virions following transfection of HeLa cells, as
determined by p24 antigen capture assay (data not shown).
Interestingly, the virion-associated RT activity measured at 39.5°C
was approximately fourfold lower than that determined at 34.5°C.
Postulating that the mt1 mutation might be located within a potential
ts region of the HIV-1 RT and that the four-residue alanine
substitution might be too incapacitating, three additional mutants (mt2
to mt4) were constructed. As shown in Table
2, a lysine-to-alanine substitution at
residue 65 (mt1 and mt3) resulted in loss of infectivity at all
temperatures, and replacement of only residues 66 and 67 (mt2) resulted
in a virus with a wild-type phenotype. Only mt4, with alanine
substitutions at amino acids 64, 66, and 67, exhibited a consistent
ts phenotype following infection of CEM (12D7) cells.
The infection kinetics of the HIV-1 mutant mt4 and its wild-type
HIV-1
LAI parent at 34.5, 37, and 39.5°C in transfected
CEM
(12D7) cells are presented in Fig.
1.
The spread of wild-type
virus throughout the infected cultures,
monitored by both peak
RT activity and p24 antigen released into the
supernatant medium,
was greatest at 37°C, somewhat diminished at
39.5°C, and markedly
reduced at 34.5°C. In contrast, mt4 exhibited
virtually no infectivity
at 39.5°C, as measured by RT activity or p24
production. At the
permissive temperature of 34.5°C, mt4 infectivity,
as measured
by p24 antigen capture, was indistinguishable from that of
the
wild-type HIV-1
LAI. When monitored by release of RT
activity into
the medium, the spread of mt4 through the CEM (12D7) cell
cultures
relative to wild-type HIV-1
LAI was inversely
related to incubation
temperature.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Replication kinetics of mt4 (mt) and its wild-type
HIV-1LAI parent (wt) in CEM (12D7) cells. CEM cells were
transfected with the indicated proviral DNAs as described in Materials
and Methods. Cells were incubated at 34.5°C (top), 37°C (middle),
or 39.5°C (bottom) and were split 1:3 (37 and 39.5°C) or 1:2
(34.5°C) every 2 days. RT activity in the supernatant was monitored
at the indicated times (left panels). Release of
p24gag into the medium was also determined at
the peak of RT production (right panels). The amount of
p24gag detected in duplicate samples of
supernatant medium collected from cells transfected with the wild-type
HIV-1LAI proviral DNA at 37°C was arbitrarily set to
100%.
|
|
A ts defect is observed during the production of mt4
particles at the nonpermissive temperature.
To ascertain whether
the observed loss of mt4 infectivity at 39.5°C reflected impaired
synthesis, processing, assembly, or release of progeny virions at the
restrictive temperature, HeLa cells, which lack surface CD4 and
therefore support only the postintegration steps of the virus life
cycle, were transfected with wild-type or mt4 mutant viral DNA at
various temperatures, and the properties of the particles released into
the medium were examined (Table 3). The
RT activity associated with mt4 particles produced at 34.5°C was
readily detected when assayed at 34.5, 37, and 39.5°C, although the
levels measured were consistently two- to threefold lower than
wild-type virus levels. In contrast, the RT activity associated with
mt4 produced at 39.5°C was 34- to 57-fold lower than that of the
wild-type HIV-1LAI, irrespective of the temperature at
which the RT assay was conducted. Thus, mutant particles produced at
the nonpermissive temperature displayed greatly reduced RT activity.
However, equivalent numbers of mt4 and HIV-1LAI progeny virions, as measured by p24 antigen levels in the culture supernatants, were released from the transfected HeLa cells at the permissive and
nonpermissive temperatures (Table 3).
A similar phenotype was observed in the single-cycle MAGI cell
infectivity assay. HIV-1 mutant mt4 produced at 34.5°C displayed
infectivities indistinguishable from those of wild-type virus
at all
assay temperatures, whereas mutant particles generated
at 39.5°C
exhibited only background levels of

-galactosidase
activity compared
to HIV-1
LAI (Table
4).
Because reverse transcription
of the viral genome is a required step
for infectivity in MAGI
cells, these results indicate that the RT
incorporated into mt4
at the permissive temperature is fully capable of
directing the
synthesis of viral DNA in infected cells at the
nonpermissive
temperature.
mt4 particles produced at the nonpermissive temperature lack RT
protein.
When it became apparent that the ts phenotype
of HIV-1 mutant mt4 was a property of progeny virions produced at
39.5°C but not at 34.5°C, the synthesis, processing, and
incorporation of RT and other pol gene products were
examined at both temperatures to ascertain which step(s) in the virus
life cycle was temperature dependent. Cultures of CEM (12D7) cells,
transfected for several days with wild-type or mt4 viral DNA at the
semipermissive temperature of 36.5°C, were metabolically labeled with
[35S]methionine for 16 or 12 h at 34.5 or 39.5°C,
respectively. Cell-associated proteins were immunoprecipitated with
serum from an AIDS patient (Fig. 2A);
virion-associated proteins were immunoprecipitated with the same
patient serum (Fig. 2A), two anti-HIV-1 RT polyclonal antibodies (Fig.
2B), or an anti-HIV-1 IN monoclonal antibody (Fig. 2C). All
immunoprecipitated proteins were then resolved by SDS-PAGE.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Radioimmunoprecipitation analysis of HIV-1 proteins
produced in transfected CEM (12D7) cells at the nonpermissive
temperature. CEM cells were transfected with the indicated DNAs (wt,
HIV-1LAI proviral DNA; mt, mt4 proviral DNA; mock, pUC19)
and were maintained at 36 ± 0.5°C. About 11 days
posttransfection, the cells were shifted to 39.5°C and metabolically
labeled at this temperature with [35S]Met for 12 h
as described in Materials and Methods. (A) Cell-associated or
virion-associated HIV-1 proteins were immunoprecipitated with serum
from an AIDS patient. Virion-associated proteins were also subjected to
immunoprecipitation with anti-HIV-1 RT Ab 1 and Ab 2 (B) or with an
anti-HIV-1 IN monoclonal antibody (C). All immunoprecipitated proteins
were resolved on SDS-10% polyacrylamide-AcrylAide gels. The positions
of the gp160 envelope glycoprotein precursor, the gp120 surface (SU)
envelope glycoprotein, the 66- and 51-kDa RT subunits, the 55-kDa Gag
precursor [Pr55gag], the 32-kDa IN
[p32(IN)], and the 24-kDa capsid protein [p24(CA)] are indicated at
the right; the positions of molecular weight standards are shown on the
left.
|
|
The electropherogram of virion-associated proteins, present in
particles produced at 39.5°C and immunoprecipitated with AIDS
patient
serum, revealed the presence of multiple HIV-1 structural
proteins in
both the wild-type and mutant virus preparations (Fig.
2A). Notably
missing or present at near background levels in samples
of mt4 produced
at the nonpermissive temperature was the 66-kDa
subunit of RT. To
confirm the absence of particle-associated RT
protein, the same samples
of HIV-1
LAI and mt4, produced at 39.5°C
but
immunoprecipitated with two different polyclonal antibodies
directed
against HIV-1 RT, were similarly analyzed. As shown in
Fig.
2B, p66 was
immunoprecipitated from wild-type virions but
not from the mutant
particles with both anti-RT antibodies. Anti-RT
Ab 2 also
immunoprecipitated the 51-kDa RT subunit from the wild-type
virus
sample but significantly reduced amounts of p51 from the
preparation of
mutant virions (Fig.
2B, right).
The Pr160gag-pol precursor is synthesized
and incorporated into mt4 particles produced at the nonpermissive
temperature.
Several explanations can be entertained to account
for the absence of the heterodimeric RT protein in mutant virions
generated at the nonpermissive temperature. It is possible that the
Gag-Pol precursor polyprotein is not synthesized at 39.5°C or is so
unstable that none of the proteins encoded by the pol gene
are assembled into progeny virions. From the data presented thus far,
this cannot be the case. The HIV-1 Pr160gag-pol
precursor becomes incorporated into nascent virions and is processed into the mature PR, RT, and IN proteins during or immediately following
release of particles from productively infected cells. The presence of
fully active protease in mt4 particles produced at the nonpermissive
temperature can be inferred from the presence of several
virion-associated Gag cleavage products, including p24 (Fig. 2A). The
AIDS patient antiserum used in that experiment also immunoprecipitated
a 32-kDa protein from both wild-type and mutant virus particles with an
electrophoretic mobility consistent with HIV-1 IN, another product of
the processed Pr160gag-pol. Confirmation that
this was indeed the IN protein was obtained by immunoprecipitating mt4,
generated at 39.5°C, with an anti-HIV-1 IN monoclonal antibody (Fig.
2C); a prominent 32-kDa band was observed in samples of both wild-type
and mutant virus particles.
The presence of the protease and IN proteins but not the RT heterodimer
in mutant virions produced at the nonpermissive temperature
suggested
that RT was either aberrantly processed or proteolytically
degraded
after the incorporation of the Pr160
gag-pol
precursor into budding virions. This possibility was first examined
by
pulse-labeling mt4-infected CEM (12D7) cells, maintained at
34.5 or
39.5°C, for 30 min followed by a 4-h chase. Figure
3 shows
that cell-associated
Pr160
gag-pol was synthesized at both
temperatures and that increasing levels
of p66 RT and p32 IN appeared
in the progeny virions released
from cells at 34.5°C. At 39.5°C,
however, little if any p66 was
associated with virus particles, even
after only 30 min of chase,
nor was free, non-virion-associated p66
shed into the supernatant
medium at the restrictive temperature (data
not shown).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 3.
Pulse-chase analysis of mt4 viral protein expression and
release from transfected CEM (12D7) cells at permissive and
nonpermissive temperatures. CEM (12D7) cells were transfected with mt4
proviral DNA and maintained at 36 ± 0.5°C for approximately 11 days. The cells were then split, pulse-labeled with
[35S]Met for 30 min, and chased in unlabeled medium for
the indicated times at either 34.5 or 39.5°C. At each time point,
equal aliquots were removed and separated into cell-associated and
virion-associated fractions (the cell-associated fraction was collected
at the end of the pulse period since a preliminary experiment indicated
that negligible amounts of viral proteins had been released into the
medium at that time). Lysates from each fraction were
immunoprecipitated with AIDS patient sera and then resolved on
SDS-10% polyacrylamide-AcrylAide gels. The positions of the HIV-1
marker proteins (described in the legend to Fig. 2) and molecular
weight standards are shown.
|
|
To definitively demonstrate that the Gag-Pol precursor encoded by mt4
was incorporated into nascent particles at 39.5°C, the
PR coding
sequence was inactivated in the context of both the
wild type and the
temperature-sensitive mutant, and progeny virions
released from HeLa
cells were examined for the presence of unprocessed
Pr160
gag-pol. A preliminary experiment revealed
that HeLa cells, labeled with
[
35S]methionine for 12 h, 40 h following transfection with cloned
mt4 DNA at the
nonpermissive temperature, released virus particles
containing little
or no p66 and p51 (Fig.
4A). An
Asp-to-Asn substitution
was then introduced at residue 25 of PR into
both HIV-1
LAI and
mt4 cloned DNAs, which were then
transfected into HeLa cells maintained
at 39.5°C. This mutation in
the HIV-1 PR had previously been shown
to eliminate HIV-1 PR activity
(
35). As expected for HIV-1 PR

mutants, the
cell-associated and virion-associated samples contained
unprocessed
Pr55
gag (Fig.
4B). More importantly, both the
HIV-1
LAI and mt4 progeny
virions contained nearly
equivalent amounts of the Pr160
gag-pol (Fig.
4B,
right), confirming that the Gag-Pol precursor encoded
by mt4 was, in
fact, incorporated into virus particles at 39.5°C.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of wild-type and ts mutant viral
proteins produced in transfected HeLa cells. HeLa cells were
transfected with the indicated plasmids (wt, HIV-1LAI
proviral DNA; mt, mt4 proviral DNA; PR , PR-defective
proviral DNA; PR /mt, mt4 proviral DNA with a mutated PR;
mock, pUC19). (A) Forty-eight hours posttransfection, viral particles
were harvested from the cells incubated at either 34.5 or 39.5°C.
Virion-associated proteins were analyzed by immunoblotting using the
anti-HIV-1 RT polyclonal antibody described in Materials and Methods.
(B) Forty-eight hours posttransfection, the HeLa cells were
metabolically labeled with [35S]Met at 39.5°C for
12 h. Cell-associated or virion-associated proteins were
immunoprecipitated with an AIDS patient serum and resolved on SDS-10%
polyacrylamide-AcrylAide gels. The markers used are described in the
legend to Fig. 2.
|
|
 |
DISCUSSION |
The charged cluster of amino acids (KKKD) mutated by alanine
substitution in this study (residues 64 to 67) is situated in the
finger domain of the 66-kDa subunit of HIV-1 RT, within a loop
connecting beta sheets
3 and
4 (23, 28, 44). Three of
these residues are also included within a highly conserved retroviral
RT motif (IKKK), consisting of a highly hydrophobic amino acid (I or V)
followed by at least two basic amino acids. For lentiviruses and the
Mason-Pfizer monkey virus, three lysines follow an initial isoleucine.
From structural analyses, it has been proposed that this region of RT
is involved in the interaction of the enzyme with the primer
(8).
Several mutations affecting HIV-1 RT residues 64 to 67 have been
previously reported. For example, the substitution of arginine for
lysine 65 results in >95% loss of RNA-dependent DNA-polymerizing activity, as measured in bacterial lysates containing 66-kDa
homodimeric forms of RT (5, 6); this mutation had no
detectable effect on RNase activity. In contrast, mutagenesis of
lysines 64 and 66 (K to R) had only modest or no significant effects,
respectively, on either polymerizing or RNase H activity (5, 6,
26). More recent analyses of a lysine-to-arginine substitution at
codon 65 (K65R) of the HIV-1 RT, associated with the emergence of
resistance to 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyinosine (ddI),
and the (
) enantiomer of 2',3'-dideoxy-3'-thiacytidine (15, 17, 18, 56), revealed no loss of infectivity of the resultant virus
when assayed in MT-4 cells or activated peripheral blood mononuclear
cells. As noted in Table 2, any RT mutant containing an
alanine-for-lysine substitution at residue 65 (viz., mt1 or mt3) was
replication incompetent in CEM (12D7) cells. These results suggest that
for the establishment of a spreading virus infection, a positively
charged amino acid must be present at this position of the HIV-1 RT; an
uncharged alanine substitution causes loss of infectivity.
Mutant mt4 particles produced at the nonpermissive temperature contain
little or no detectable p66-p51 heterodimeric RT protein. This property
is very similar to that described for an RT variant that emerged
following exposure to (alkylamino)piperidine
bis(heteroaryl)piperizines in vitro. This G190E RT revertant exhibited
marked reductions in both particle-associated RT activity and
heterodimeric RT protein levels, the latter measured by immunoblotting
with a polyclonal antibody to the HIV-1 RT (39). One could
argue that our inability to detect the 66- and 51-kDa RT subunits in
mt4 particles produced at 39°C merely reflected the failure of the
antibodies used to bind to the mutant RT proteins. This seems highly
unlikely because the same results were obtained with a variety of
antibody preparations (AIDS patient serum, two different rabbit
anti-HIV-1 RT polyclonal antibodies, and two different anti-HIV-1 RT
monoclonal antibodies [data not shown]) in both immunoprecipitation
and immunoblotting assays.
Because the 66- or 51-kDa RT subunits have unique conformations within
the precursor homodimer and mature RT heterodimer, the ts
mutant mt4 described in this study may be useful in delineating the
role(s) of each subunit during its assembly into a stable and
functional viral polymerase. At present, we can only speculate about
the mechanism responsible for the absence, and presumed degradation, of
the two RT protein subunits in mt4 produced at the nonpermissive
temperature. Nonetheless, several aspects of this temperature-dependent
phenomenon are unambiguous. First, Pr160gag-pol
containing the ts RT mutation is incorporated into progeny
virions at 39°C. Second, as long as the mutant RT remains a component of the Gag-Pol precursor, it is stably maintained within virus particles produced under nonpermissive conditions. Third, the mutant
p66-p51 heterodimeric RT, formed at 34.5°C, is biochemically and
functionally stable at 39°C. This last property, in conjunction with
the results of a pulse-chase experiment (Fig. 3) showing that
cell-associated Pr160gag-pol is converted to
detectable 66-kDa particle-associated RT within a 30-min chase period
at 34.5 but not 39°C, indicates that the mutant p66-p51 heterodimer
is very rapidly degraded.
Extracts from bacteria expressing the HIV-1 RT contain the p66-p66
homodimer, which is in equilibrium with p66 monomer, as well as a
p66-p51 heterodimer. The latter is a bacterial protease cleavage
product of either monomeric or dimeric p66 or both (10, 20, 31,
37, 38, 42, 46, 48). All of these structures possess unique
physical and chemical properties (42). For example, the
dissociation constant for the p66-p51 heterodimer has been reported to
be 10
9 M or lower, compared to 10
5 M for
the p66-p66 homodimer. Furthermore, because the site that must be
cleaved to generate p51 is situated within a relatively inaccessible
region of the N-terminal
sheet of RNase H, it has been proposed
that the p66-p66 homodimer assumes a structurally asymmetric, and
possibly less stable, conformation, thereby exposing the C-terminal
RNase domain on one of the subunits for digestion by PR (28,
49). During virus replication, p66-p51 heterodimers arise as a
result of cleavage of HIV-1 Pr160gag-pol by the
viral PR. It is very likely that other intermediates are also generated
during the processing reaction and that the presence of the
ts mutation further destabilizes one of these RT
intermediates, rendering it less resistant to degradation by the HIV-1
PR and/or cellular PRs at the nonpermissive temperature.
The charged-cluster-to-alanine mutagenesis strategy would be expected
to alter residues located on solvent-exposed protein surfaces and
possibly interfere with electrostatic interactions with other
molecules. In the case of the human growth hormone, this mutagenesis
approach resulted in the identification of residues involved in hormone
binding (1). In general, charged-cluster-to-alanine mutagenesis has also resulted in high frequencies of ts
cellular and viral mutants (12, 19, 50). For example, 9 of
26 substitutions affecting the poliovirus RNA-dependent RNA polymerase
resulted in conditional mutants defective in RNA synthesis
(12). This is to be contrasted with the results reported in
this study, where only 1 of 33 HIV-1 RT mutants was ts, and
a previous report describing a single conditional HIV-1 IN mutant of
the 24 constructed (55). It is not clear why so few
ts mutants of HIV-1 pol gene products have been
obtained by this mutagenesis strategy. However, it is interesting to
note that the charged-cluster-to-alanine ts HIV-1 mutants
affected a step(s) involving virion assembly, not the catalytic
functions of RT or IN. Instead, the conditional phenotype exhibited by
HIV-1 mutant mt4 described in this report most likely reflects the
altered interaction of the RT precursor and RT subunits with other
virion components and results in the degradation of an RT intermediate
subsequent to its cleavage from the Gag-Pol precursor. Less can be said
about the nature of the defect in the previously reported ts
HIV-1 IN mutant (55). In contrast to our results, the IN
protein was detected in virus particles produced at the nonpermissive
temperature. Since neither mutation impairs enzymatic activity, one
could speculate that, like the ts RT mutant, the mutated
virion-associated IN protein may be unable to assemble into
functionally active IN oligomers, form stable associations with viral
and cellular DNA targets, or associate with other viral and cellular
proteins during the early phase of productive infection.
 |
ACKNOWLEDGMENTS |
We are grateful to Bachoti Rao for sequencing the different
ts RT mutants and thank Eric Freed and Stephen Hughes for
suggestions and comments on the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Molecular Microbiology, NIAID, NIH, 4 Center Dr., Building 4, Room 315, Bethesda, MD 20892-0460. Phone: (301) 496-4012. Fax: (301) 402-0226. E-mail: malm{at}NIH.gov.
Present address: Laboratory of Antiviral Drug Mechanisms, SAIC
Frederick, NCI-FCRDC, Frederick, MD 21702.
 |
REFERENCES |
| 1.
|
Bass, S. H.,
M. G. Mulkerrin, and J. A. Well.
1991.
A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor.
Proc. Natl. Acad. Sci. USA
88:4498-4502[Abstract/Free Full Text].
|
| 2.
|
Beard, W. A.,
S. J. Stahl,
H. R. Kim,
K. Bebenek,
A. Kumar,
M. P. Strub,
S. P. Becerra,
T. A. Kunkel, and S. H. Wilson.
1994.
Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain.
J. Biol. Chem.
269:28091-28097[Abstract/Free Full Text].
|
| 3.
|
Beard, W. A., and S. H. Wilson.
1994.
Site-directed mutagenesis of HIV reverse transcriptase to probe enzyme processivity and drug binding.
Curr. Opin. Biotechnol.
5:414-421[Medline].
|
| 4.
|
Beard, W. A.,
D. T. Minnick,
C. L. Wade,
R. Prasad,
R. L. Won,
A. Kumar,
T. A. Kunkel, and S. A. Wilson.
1996.
Role of the helix clamp in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis.
J. Biol. Chem.
271:12213-12220[Abstract/Free Full Text].
|
| 5.
|
Boyer, P. L.,
A. I. Ferris, and S. H. Hughes.
1992.
Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.
J. Virol.
66:1031-1039[Abstract/Free Full Text].
|
| 6.
|
Boyer, P. L.,
A. L. Ferris, and S. H. Hughes.
1992.
Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase.
J. Virol.
66:7533-7537[Abstract/Free Full Text].
|
| 7.
|
Boyer, P. L.,
A. I. Ferris,
P. Clark,
J. Whitmer,
P. Frank,
C. Tantillo,
E. Arnold, and S. H. Hughes.
1994.
Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase.
J. Mol. Biol.
243:472-483[Medline].
|
| 8.
|
Boyer, P. L.,
C. Tantillo,
A. Jacobo-Molina,
R. G. Nanni,
J. Ding,
E. Arnold, and S. H. Hughes.
1994.
Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.
Proc. Natl. Acad. Sci. USA
91:4882-4886[Abstract/Free Full Text].
|
| 9.
|
Chao, S.-F.,
V. L. Chan,
P. Juranka,
A. H. Kaplan,
R. Swanstrom, and C. A. Hutchison, III.
1995.
Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.
Nucleic Acids Res.
23:803-810[Abstract/Free Full Text].
|
| 10.
|
Clark, P. K.,
A. L. Ferris,
D. A. Miller,
A. Hizi,
K. W. Kim,
S. M. Deringer-Boyer,
M. L. Mellini,
A. D. Clark,
G. F. Atnold, and W. B. Lebherz, III.
1990.
HIV-1 reverse transcriptase purified from a recombinant strain of E. coli.
AIDS Res. Hum. Retroviruses
6:753-764[Medline].
|
| 11.
|
DeClerq, E.
1994.
HIV resistance to reverse transcriptase inhibitors.
Biochem. Pharmacol.
47:155-169[Medline].
|
| 12.
|
Diamond, S. E., and K. Kirkegaard.
1994.
Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis.
J. Virol.
68:863-876[Abstract/Free Full Text].
|
| 13.
|
di Marzo Veronese, F.,
T. D. Copeland,
A. L. DeVico,
R. Rahman,
S. Oroszlan,
R. C. Gallo, and M. G. Sarngadharan.
1986.
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.
Science
231:1289-1291[Abstract/Free Full Text].
|
| 14.
|
Freed, E. O., and M. A. Martin.
1994.
Evidence for a functional interaction between the V1/V2 and CD4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.
J. Virol.
68:2503-2512[Abstract/Free Full Text].
|
| 15.
|
Gao, Q.,
Z. Gu,
M. A. Parniak,
J. Cameron,
N. Cammack,
C. Boucher, and M. A. Wainberg.
1993.
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the ( ) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Antimicrob. Agents Chemother.
37:1390-1392[Abstract/Free Full Text].
|
| 16.
|
Ghosh, M.,
P. S. Jacques,
D. W. Rodgers,
M. Ottman,
J.-L. Darlix, and S. F. J. Le Grice.
1996.
Alternations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization.
Biochemistry
35:8553-8562[Medline].
|
| 17.
|
Gu, Z.,
Q. Gao,
H. Fang,
H. Salomon,
M. A. Parniak,
E. Goldberg,
J. Cameron, and M. A. Wainberg.
1994.
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytine.
Antimicrob. Agents Chemother.
38:275-281[Abstract/Free Full Text].
|
| 18.
|
Gu, Z.,
R. S. Fletcher,
E. J. Arts,
M. A. Wainberg, and M. A. Parniak.
1994.
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2',3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
J. Biol. Chem.
269:28118-28122[Abstract/Free Full Text].
|
| 19.
|
Hassett, D. E., and R. C. Condit.
1994.
Targeted construction of temperature-sensitive mutations in vaccinia virus by replacing clustered charged residues with alanine.
Proc. Natl. Acad. Sci. USA
91:4554-4558[Abstract/Free Full Text].
|
| 20.
|
Hizi, A.,
C. McGill, and S. H. Hughes.
1988.
Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in E. coli and analysis of mutants.
Proc. Natl. Acad. Sci. USA
85:1218-1222[Abstract/Free Full Text].
|
| 21.
|
Huang, M.,
J. M. Orenstein,
M. A. Martin, and E. O. Freed.
1995.
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.
J. Virol.
69:6810-6818[Abstract].
|
| 22.
|
Jacobo-Molina, A., and E. Arnold.
1991.
HIV reverse transcriptase structure-function relationship.
Biochemistry
30:6351-6361[Medline].
|
| 23.
|
Jacobo-Molina, A.,
J. Ding,
R. G. Nanni,
A. D. Clark, Jr.,
X. Lu,
C. Tantillo,
R. L. Williams,
G. Kamer,
A. L. Ferris,
P. Clark,
A. Hizi,
S. H. Hughes, and E. Arnold.
1993.
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA.
Proc. Natl. Acad. Sci. USA
90:6320-6324[Abstract/Free Full Text].
|
| 24.
|
Jacques, P. S.,
B. M. Wohrl,
M. Ottmann,
J. L. Darlix, and S. F. J. Le Grice.
1994.
Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization.
J. Biol. Chem.
269:26472-26478[Abstract/Free Full Text].
|
| 25.
|
Kaplan, A. H.,
M. Manchester, and R. Swanstrom.
1994.
The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.
J. Virol.
68:6782-6786[Abstract/Free Full Text].
|
| 26.
|
Kim, B.,
T. R. Hathaway, and L. A. Loeb.
1996.
Human immunodeficiency virus reverse transcriptase. Functional mutants obtained by random mutagenesis coupled with genetic selection in Escherichia coli.
J. Biol. Chem.
271:4872-4878[Abstract/Free Full Text].
|
| 27.
|
Kimpton, J., and M. Emerman.
1992.
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated -galactosidase gene.
J. Virol.
66:2232-2239[Abstract/Free Full Text].
|
| 28.
|
Kohlstaedt, L. A.,
J. Wang,
J. M. Friesman,
P. A. Rice, and T. A. Steitz.
1992.
Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complex with an inhibitor.
Science
256:1783-1790[Abstract/Free Full Text].
|
| 29.
|
Kunkel, T. A.,
J. D. Roberts, and R. A. Zakour.
1987.
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Methods Enzymol.
154:367-382[Medline].
|
| 30.
|
Larder, B.,
D. Purifor,
K. Powell, and G. Darby.
1987.
AIDS virus reverse transcriptase defined by high level expression in E. coli.
EMBO J.
6:3133-3137[Medline].
|
| 31.
|
Larder, B.,
D. Purifor,
K. Powell, and G. Darby.
1987.
Site-specific mutagenesis of AIDS virus reverse transcriptase.
Nature (London)
327:716-717[Medline].
|
| 32.
| Larder, B. A. 1995. Viral resistance and the
selection of antiviral combinations. J. Acquired Immune Defic. Syndr.
Hum. Retrovirol. 10(Suppl. 1):S28-S33.
|
| 33.
|
Larder, B. A.,
S. D. Kemp, and D. Purifor.
1989.
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
Proc. Natl. Acad. Sci. USA
86:4803-4807[Abstract/Free Full Text].
|
| 34.
|
Le Grice, S. F. J.,
T. Naas,
B. Wohlgensinger, and O. Schatz.
1991.
Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.
EMBO J.
10:3905-3911[Medline].
|
| 35.
|
Loeb, D. D.,
R. Swanstrom,
L. Everitt,
M. Manchester,
S. E. Stamper, and C. A. Hutchison, III.
1989.
Complete mutagenesis of the HIV-1 protease.
Nature (London)
340:391-400[Medline].
|
| 36.
|
Lowe, D. M.,
A. Aitken,
C. Bradley,
G. K. Darby,
B. A. Larder,
K. L. Powell,
D. J. Purifoy,
M. Tisdale, and D. K. Stammers.
1988.
HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
Biochemistry
27:8884-8889[Medline].
|
| 37.
|
Lowe, D. M.,
V. Parmor,
S. D. Kemp, and B. A. Larder.
1991.
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase.
FEBS Lett.
282:231-234[Medline].
|
| 38.
|
Muller, B.,
T. Restle,
S. Weiss,
M. Gautel,
G. Sczakiel, and R. S. Goody.
1989.
Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli.
J. Biol. Chem.
264:13975-13978[Abstract/Free Full Text].
|
| 39.
|
Olmsted, R. A.,
D. E. Slade,
L. A. Kopta,
S. M. Poppe,
T. J. Poel,
S. W. Newport,
K. B. Rank,
C. Biles,
R. A. Morge,
T. J. Dueweke,
Y. Yagi,
D. L. Romero,
R. C. Thomas,
S. K. Sharma, and W. G. Tarpley.
1996.
(Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
J. Virol.
70:3698-3705[Abstract].
|
| 40.
|
Park, J., and C. D. Morrow.
1992.
The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.
J. Virol.
66:6304-6313[Abstract/Free Full Text].
|
| 41.
|
Peden, K.,
M. Emerman, and L. Montagnier.
1991.
Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1 LAI, HIV-1 MAL, and HIV-1 ELI.
Virology
185:661-672[Medline].
|
| 42.
|
Restle, T.,
B. Muller, and R. S. Goody.
1990.
Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention.
J. Biol. Chem.
265:8986-8988[Abstract/Free Full Text].
|
| 43.
|
Richman, D. D.
1993.
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.
Antimicrob. Agents Chemother.
37:1207-1213[Free Full Text].
|
| 44.
|
Rodgers, D. W.,
S. J. Gamblin,
B. A. Harris,
S. Ray,
J. S. Culp,
B. Hellmig,
D. J. Woolf,
C. Debouck, and S. C. Harrison.
1995.
The structure of unligated reverse transcriptase from human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
92:1222-1226[Abstract/Free Full Text].
|
| 45.
|
Ross, E. K.,
A. J. Buckler-White,
A. B. Rabson,
G. Englund, and M. A. Martin.
1991.
Contribution of NF- B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.
J. Virol.
65:4350-4358[Abstract/Free Full Text].
|
| 46.
|
Rowley, G. L.,
Q. F. Ma,
I. C. Bathurst,
P. J. Barr, and G. L. Kenyon.
1990.
Stabilization and activation of recombinant human immunodeficiency virus-1 reverse transcriptase-P66.
Biochem. Biophys. Res. Commun.
167:673-679[Medline].
|
| 47.
|
Smith, A. J.,
N. Srinivasakumar,
M.-L. Hammarskjold, and D. Rekosh.
1993.
Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.
J. Virol.
67:2266-2275[Abstract/Free Full Text].
|
| 48.
|
Tanese, N.,
V. R. Prasad, and S. P. Goff.
1988.
Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase.
DNA
7:407-416[Medline].
|
| 49.
|
Wang, J.,
S. J. Smerdon,
J. Jager,
L. A. Kohlstaedt,
P. A. Rice,
J. M. Friedman, and T. A. Steitz.
1994.
Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer.
Proc. Natl. Acad. Sci. USA
91:7242-7246[Abstract/Free Full Text].
|
| 50.
|
Wertman, K. F.,
D. G. Drubin, and D. Botstein.
1992.
Systematic mutational analysis of yeast ACT1 gene.
Genetics
132:337-350[Abstract].
|
| 51.
|
Willey, R. L.,
D. H. Smith,
L. A. Lasky,
T. S. Theodore,
P. L. Earl,
B. Moss,
D. J. Capon, and M. A. Martin.
1988.
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
J. Virol.
62:139-147[Abstract/Free Full Text].
|
| 52.
|
Willey, R. L.,
J. S. Bonifacino,
B. J. Potts,
M. A. Martin, and R. D. Klausner.
1988.
Biosynthesis, cleavage and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gp160.
Proc. Natl. Acad. Sci. USA
85:9580-9584[Abstract/Free Full Text].
|
| 53.
|
Willey, R. L.,
T. Klimkait,
D. M. Frucht,
J. S. Bonifacino, and M. A. Martin.
1991.
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.
Virology
184:319-329[Medline].
|
| 54.
|
Wills, J., and R. C. Craven.
1991.
Form, function, and use of retroviral gag proteins.
AIDS
5:639-654[Medline]. (Editorial.)
|
| 55.
|
Wiskerchen, M., and M. A. Muesing.
1995.
Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene.
J. Virol.
69:597-601[Abstract].
|
| 56.
|
Zhang, D.,
A. M. Caliendo,
J. J. Eron,
K. M. DeVore,
J. C. Kaplon,
M. S. Hirsch, and R. T. D'Aquila.
1994.
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.
Antimicrob. Agents Chemother.
38:282-287[Abstract/Free Full Text].
|
J Virol, March 1998, p. 2047-2054, Vol. 72, No. 3
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dunn, L. L., McWilliams, M. J., Das, K., Arnold, E., Hughes, S. H.
(2009). Mutations in the Thumb Allow Human Immunodeficiency Virus Type 1 Reverse Transcriptase To Be Cleaved by Protease in Virions. J. Virol.
83: 12336-12344
[Abstract]
[Full Text]
-
Matusan, A. E., Kelley, P. G., Pryor, M. J., Whisstock, J. C., Davidson, A. D., Wright, P. J.
(2001). Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus. J. Gen. Virol.
82: 1647-1656
[Abstract]
[Full Text]
-
Dettenhofer, M., Yu, X.-F.
(1999). Proline Residues in Human Immunodeficiency Virus Type 1 p6Gag Exert a Cell Type-Dependent Effect on Viral Replication and Virion Incorporation of Pol Proteins. J. Virol.
73: 4696-4704
[Abstract]
[Full Text]